Search results for "2725 Infectious Diseases"

showing 10 items of 18 documents

The protein and microRNA cargo of extracellular vesicles from parasitic helminths – current status and research priorities

2020

Helminth parasites have a remarkable ability to persist within their mammalian hosts, which is largely due to their secretion of molecules with immunomodulatory properties. Although the soluble components of helminth secretions have been extensively studied, the discovery that helminths release extracellular vesicles (EVs) has added further complexity to the host-parasite interaction. Whilst several studies have begun to characterise the molecules carried by helminth EVs, work aimed at investigating their biological functions has been hindered by a lack of helminth-specific EV markers. To begin to address this, we summarised helminth EV literature to date. With a focus on the protein and mi…

0301 basic medicine10078 Institute of ParasitologyPARASITES2405 ParasitologyHelminthiasisPROTEINExosomes//purl.org/becyt/ford/1 [https]0302 clinical medicine600 TechnologyCladeMICROVESICLESProtein.MicroRNAHelminth ProteinsInfectious DiseasesMicrovesiclesProtein family030231 tropical medicine610 Medicine & healthBiologyCARGO03 medical and health sciencesExtracellular VesiclesHelminthsmicroRNAparasitic diseasesHelminthsAnimalsHumansParasites//purl.org/becyt/ford/1.6 [https]EXOSOMESMICRORNAEXTRACELLULAR VESICLES2725 Infectious Diseasesbiology.organism_classificationMicrovesiclesBiomarker (cell)MicroRNAs030104 developmental biologyNematodeEvolutionary biology570 Life sciences; biologyHELMINTHSParasitologyRNA HelminthFunction (biology)BiomarkersCargo
researchProduct

Fate-Mapping of GM-CSF Expression Identifies a Discrete Subset of Inflammation-Driving T Helper Cells Regulated by Cytokines IL-23 and IL-1β.

2019

Summary Pathogenic lymphocytes initiate the development of chronic inflammatory diseases. The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) (encoded by Csf2) is a key communicator between pathogenic lymphocytes and tissue-invading inflammatory phagocytes. However, the molecular properties of GM-CSF-producing cells and the mode of Csf2 regulation in vivo remain unclear. To systematically study and manipulate GM-CSF+ cells and their progeny in vivo, we generated a fate-map and reporter of GM-CSF expression mouse strain (FROG). We mapped the phenotypic and functional profile of auto-aggressive T helper (Th) cells during neuroinflammation and identified the signature and pa…

0301 basic medicineMalemedicine.medical_treatmentImmunologyInterleukin-1betaInflammation610 Medicine & health10071 Functional Genomics Center ZurichBiology10263 Institute of Experimental Immunology03 medical and health sciencesInterferon-gammaMice0302 clinical medicineFate mappingImmunopathologymedicineInterleukin 23Immunology and AllergyAnimalsReceptorNeuroinflammationReceptors CXCR6InflammationMice KnockoutReceptors Interleukin-1 Type I2403 ImmunologyTumor Necrosis Factor-alphaGranulocyte-Macrophage Colony-Stimulating Factor2725 Infectious DiseasesReceptors InterleukinTh1 CellsPhenotype3. Good healthCell biology10040 Clinic for NeurologyMice Inbred C57BL030104 developmental biologyInfectious DiseasesCytokine030220 oncology & carcinogenesis2723 Immunology and AllergyInterleukin-23 Subunit p19570 Life sciences; biologyTh17 CellsFemalemedicine.symptomImmunity
researchProduct

Fasciola hepatica eggs in paleofaeces of the Persian onager Equus hemionus onager, a donkey from Chehrabad archaeological site, dating back to the Sa…

2018

Fascioliasis is a highly pathogenic zoonotic disease caused by the liver trematodes Fasciola hepatica and F. gigantica. Within the multidisciplinary initiative against this disease, there is the aim of understanding how this disease reached a worldwide distribution, with important veterinary and medical repercussions, by elucidating the spreading steps followed by the two fasciolids from their paleobiogeograhical origins. Fasciola eggs were detected in paleofaeces of a donkey, probably the present-day endangered Persian onager Equus hemionus onager, found in the Chehrabad salt mine archaeological site, Zanjan province, northwestern Iran. The biological remains dated back to the Sassanid per…

0301 basic medicineMicrobiology (medical)Fascioliasis030231 tropical medicine610 Medicine & healthPersian onagerIranMicrobiology2726 Microbiology (medical)03 medical and health sciences0302 clinical medicine1311 GeneticsHepaticaparasitic diseasesGenetics1312 Molecular BiologyAnimalsDomesticationMolecular BiologyHistory AncientEcology Evolution Behavior and SystematicsMiddle EastFasciolabiologybusiness.industry2404 MicrobiologyEquidae2725 Infectious DiseasesFasciola hepatica030108 mycology & parasitologybiology.organism_classificationEquusArchaeologyHistory MedievalInfectious Diseases1105 Ecology Evolution Behavior and Systematics11294 Institute of Evolutionary MedicineLivestockDonkeybusiness
researchProduct

Lymphatic Endothelial Cells Control Initiation of Lymph Node Organogenesis

2017

Lymph nodes (LNs) are strategically situated throughout the body at junctures of the blood vascular and lymphatic systems to direct immune responses against antigens draining from peripheral tissues. The current paradigm describes LN development as a programmed process that is governed through the interaction between mesenchymal lymphoid tissue organizer (LTo) cells and hematopoietic lymphoid tissue inducer (LTi) cells. Using cell-type-specific ablation of key molecules involved in lymphoid organogenesis, we found that initiation of LN development is dependent on LTi-cell-mediated activation of lymphatic endothelial cells (LECs) and that engagement of mesenchymal stromal cells is a succeedi…

0301 basic medicinePathologymedicine.medical_specialtygovernment.form_of_governmentOrganogenesis[SDV]Life Sciences [q-bio]Immunology610 Medicine & healthMice TransgenicBiologyChoristoma10263 Institute of Experimental Immunology03 medical and health sciencesMiceImmune systemLymphotoxin beta ReceptormedicineLymph node stromal cellImmunology and AllergyAnimalsLymph nodeCells CulturedComputingMilieux_MISCELLANEOUS2403 ImmunologyReceptor Activator of Nuclear Factor-kappa BMesenchymal stem cellNF-kappa BEndothelial CellsCell DifferentiationMesenchymal Stem Cells2725 Infectious DiseasesEmbryo MammalianCell biologyMice Inbred C57BLHaematopoiesisLymphatic EndotheliumReceptors Lysosphingolipid030104 developmental biologyInfectious Diseasesmedicine.anatomical_structureLymphatic system2723 Immunology and Allergygovernment570 Life sciences; biology[SDV.IMM]Life Sciences [q-bio]/ImmunologyLymphLymph NodesSignal Transduction
researchProduct

Conditional Gene-Targeting in Mice: Problems and Solutions.

2018

0301 basic medicineTransgeneImmunologyMutagenesis (molecular biology technique)Guidelines as TopicMice Transgenic610 Medicine & healthBiology10263 Institute of Experimental ImmunologyArticleMice03 medical and health sciencesAnimalsImmunology and AllergyMice KnockoutRecombination GeneticGenetics2403 ImmunologyIntegrasesGene targeting2725 Infectious DiseasesIntegrasesMice transgenic030104 developmental biologyInfectious DiseasesMutagenesisGene Targeting2723 Immunology and Allergy570 Life sciences; biology
researchProduct

Importance of Sequence and Timing in Parasite Coinfections

2019

Coinfections by multiple parasites predominate in the wild. Interactionsbetween parasites can be antagonistic, neutral, or facilitative, and they canhave significant implications for epidemiology, disease dynamics, and evolu-tion of virulence. Coinfections commonly result from sequential exposure ofhosts to different parasites. We argue that the sequential nature of coinfectionsis important for the consequences of infection in both natural and man-madeenvironments. Coinfections accumulate during host lifespan, determining thestructure of the parasite infracommunity. Interactions within the parasite com-munity and their joint effect on the host individual potentially shape evolution ofparasi…

0301 basic medicineinfection dynamicsTime Factors030231 tropical medicineDisease epidemiology2405 ParasitologyVirulenceBiologyinfektiotHost-Parasite Interactions03 medical and health sciencessequential infection10127 Institute of Evolutionary Biology and Environmental Studies0302 clinical medicineloisetParasitic DiseasesParasite hostingAnimalsHumansParasitesepidemiologiaSequence (medicine)Transmission (medicine)Host (biology)Coinfectiondisease epidemiologymultiple infection2725 Infectious Diseasesvirulence evolutionPlantsMultiple infections030104 developmental biologyInfectious DiseasesParasitologyconcomitant infectionEvolutionary biologyta1181570 Life sciences; biology590 Animals (Zoology)Parasitology
researchProduct

European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology

2016

Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical g…

0301 basic medicinemedicine.medical_specialtyMEDLINEHigh dose intravenous immunoglobulin610 Medicine & healthEuropean Guidelines (S1) high-dose intravenous immunoglobulinDermatologySkin DiseasesDrug Administration Schedulelaw.inventionAutoimmune Diseases2708 Dermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawhemic and lymphatic diseasesintravenous immunoglobulinmedicineHumanshigh-doseEvidence-Based MedicineDose-Response Relationship Drugbusiness.industryDermatological diseases10177 Dermatology ClinicImmunoglobulins Intravenous2725 Infectious DiseasesEvidence-based medicinemedicine.diseaseDermatologyToxic epidermal necrolysisEuropeInfectious Diseases030104 developmental biologyEuropean Guidelines (S1)Dermatology clinicStevens-Johnson SyndromeInjections IntravenousEuropean Guidelines (S1) high-dose intravenous immunoglobulin dermatologyDrug MonitoringbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Guidelines for the Direct Detection ofAnaplasmaspp. in Diagnosis and Epidemiological Studies

2017

The genus Anaplasma (Rickettsiales: Anaplasmataceae) comprises obligate intracellular Gram-negative bacteria that are mainly transmitted by ticks, and currently includes six species: Anaplasma bovis, Anaplasma centrale, Anaplasma marginale, Anaplasma phagocytophilum, Anaplasma platys, and Anaplasma ovis. These have long been known as etiological agents of veterinary diseases that affect domestic and wild animals worldwide. A zoonotic role has been recognized for A. phagocytophilum, but other species can also be pathogenic for humans. Anaplasma infections are usually challenging to diagnose, clinically presenting with nonspecific symptoms that vary greatly depending on the agent involved, th…

10078 Institute of ParasitologyDirect diagnosis0301 basic medicineAnaplasma platysAnaplasmosisAnaplasmaAnaplasma bovisanimal diseases030231 tropical medicine610 Medicine & healthMicrobiology03 medical and health sciencesTicks0302 clinical medicine600 TechnologyZoonosesVirologyparasitic diseasesmedicineAnimalsHumansAnaplasmaInfecções Sistémicas e ZoonosesMicroscopybiologyIn vitro isolationAnaplasma ovis2404 Microbiology2725 Infectious DiseasesAnaplasma spp.bacterial infections and mycosesbiology.organism_classificationmedicine.diseaseVirologyAnaplasma phagocytophilumAnaplasmataceaePCR030104 developmental biologyInfectious DiseasesVertebrate hosts2406 Virology570 Life sciences; biologybacteriaAnaplasmosisRickettsialesVector-Borne and Zoonotic Diseases
researchProduct

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial inf…

2008

Background. Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. Methods. The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. Results. The pro…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAnti-HIV AgentsImmunologyantiretroviral therapyMyocardial Infarction610 Medicine & healthHIV Infections2726 Microbiology (medical)Article10234 Clinic for Infectious DiseasesCoronary artery diseasecardiovascular diseaselipidDiabetes mellitusInternal medicinemedicineHumansHIV InfectionMyocardial infarctionAdverse effectHypolipidemic AgentsHypolipidemic Agentbusiness.industryIncidenceIncidence (epidemiology)Anti-HIV AgentHIV2725 Infectious DiseasesMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious DiseasesFemalebusinessBody mass indexDyslipidemiaHuman
researchProduct

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

2013

Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. Methods Patients were randomized to receive deleobuvir 400 mg ( n=15) or 600 mg ( n=17) three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks. Interferon-free therapy was followed by response-guided faldaprevir plus pegylated interferon-α2a/ribavirin to week 24 or 48. Results…

Aminoisobutyric AcidsProline[SDV]Life Sciences [q-bio]610 Medicine & healthHepacivirusAntiviral AgentsDrug Administration SchedulePolyethylene GlycolsTherapy naive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHcv genotype 1LeucineRibavirinMedicine2736 Pharmacology (medical)Pharmacology (medical)Oral therapy030304 developmental biologyPharmacology0303 health sciencesbusiness.industryRibavirinDeleobuvirInterferon-alpha2725 Infectious DiseasesHepatitis C ChronicViral LoadVirologyRecombinant Proteins3. Good healthThiazolesInfectious DiseasesTreatment Outcome10219 Clinic for Gastroenterology and Hepatology3004 PharmacologychemistryAcrylatesFaldaprevirQuinolines030211 gastroenterology & hepatologyBenzimidazolesDrug Therapy CombinationbusinessOligopeptides
researchProduct